|Venture Round, 8/09 |
Highland Capital Partners
Fonds de solidaritÃ© FTQ
BioSyntech, Inc. develops biotherapeutic thermogels designed for tissue repair and delivery of therapeutic agents. Its technology platform is BST-Gel, a family of hydrogels based on chitosan, a natural biopolymer derived from crustacean shells. The companyâ€™s lead products in clinical trials include BSTCarGel for cartilage repair; BST-DermOn for wound healing; and BST-InPod for the treatment of chronic pain due to plantar fat pad atrophy in the heel and forefoot.
Biosyntech has a collaboration with Nicholas Piramal India, Ltd. to involve in the clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. The company was incorporated in 1994 and is headquartered in Laval, Canada.